Abstract
Genotype-guided selection of oral P2Y12 inhibitor therapy (clopidogrel versus prasugrel or ticagrelor) can reduce the incidence of bleeding in patients who have undergone primary percutaneous coronary intervention.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
